A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection Dulanermin for Injection in the Treatment of Advanced Non-small Cell Lung Cancer
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Dulanermin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Shanghai GeBaiDe Biotechnical Co
Most Recent Events
- 23 Mar 2017 New trial record